An open label trial of C-1073 (mifepristone) for psychotic major depression*
The DOI matches its Crossref record; 69 of the 71 references it cites were found in a registry or an index.
Abstract
Background The rationale for treating patients with psychotic major depression (PMD) with glucocorticosteroid receptor (GR) antagonists is explained.Methods Thirty patients with PMD, with Hamilton Rating Scale for Depression (HAMD-21) scores of 18 or greater, were assigned in an open label trial to receive 50 mg, 600 mg, or 1200 mg of mifepristone for 7 days.Results All the subjects completed the protocol; there were no dropouts. Side effects were mild and sporadic. Of 19 subjects in the combined 600- and 1200-mg group, 13 had a 30% or greater decline in their Brief Psychiatric Rating Scale (BPRS) scores, compared with 4 of 11 in the 50-mg group. In the 600- and 1200-mg group, 12 of 19 subjects showed a 50% decline in the BPRS positive symptom subscale, a more sensitive index for the symptoms seen in PMD, compared with 3 of 11 in the 50-mg group; 8 of 19 subjects in the 600- and 1200-mg group had a 50% decline in the HAMD-21, compared with 2 of 11 in the 50-mg group.Conclusions These results suggest that short term use of GR antagonists may be effective in the treatment of psychotic major depression and that further blinded studies are warranted.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Of note, depressive symptoms were considered secondary outcomes, and these trials often failed to show a significant improvement compared to placebo.”
From The HPA Axis as Target for Depression (2024) · cites this paper as [93]
In the citing paper
“4 double-blind [89-92] and 2 open-label trials [93, 94] suggested a significant reduction in psychotic symptoms, which was the primary outcome of these trials.”
From The HPA Axis as Target for Depression (2024) · cites this paper as [93]
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Decreased memory performance in healthy humans induced by stress-level cortisol treatment
Newcomer, J. W. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.6.527 · Cited by 546
Sánchez, M. M., Young, L. J., Plotsky, P. M., & Insel, T. R. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-12-04657.2000 · Cited by 420
The pharmacological treatment of delusional depression
(1985) · American Journal of Psychiatry · doi:10.1176/ajp.142.4.430 · Cited by 357
DST Studies in Psychotic Depression: A Meta-Analysis
Nelson, J. C., & Davis, J. M. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.11.1497 · Cited by 356
Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV?
(1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.6.733 · Cited by 317
Self-citationSuccessful Treatment of Cushing’s Syndrome with the Glucocorticoid Antagonist RU 486*
NIEMAN, L. K., CHROUSOS, G. P., KELLNER, C., SPITZ, I. M., NISULA, B. C., CUTLER, G. B., MERRIAM, G. R., BARDIN, C. W., & LORIAUX, D. L. (1985) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-61-3-536 · Cited by 317
Rapid Reversal of Psychotic Depression Using Mifepristone
Belanoff, J. K., Flores, B. H., Kalezhan, M., Sund, B., & Schatzberg, A. F. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200110000-00009 · Cited by 282
Self-citationDelusional and nondelusional unipolar depression: further evidence for distinct subtypes
(1981) · American Journal of Psychiatry · doi:10.1176/ajp.138.3.328 · Cited by 255
Research works printed but not linked: 9
- Ammar, 1986, Letter, Am J Psychiatry, 143, 129
- Bertagna, 1994, Administration of RU486 for 8 Days in normal volunteers, J Clin Endocrinol Metab, 78, 375
- Chrousos GP, Laue L, Nieman LK, Udelsman R, Kawai S, Loriaux DL (1989): Clinical applications of RU 486, a prototype glucocorticoid and progestin antagonist. In: The Adrenal and Hypertension: From Cloning to Clinic 57 of Serono Symposia. New York: Raven Press, pp 273–284
- Gaillard, 1984, RU 486, Med Sci, 81, 3879
- Herrmann, 1982, Effet d’un steroide anti-progesterone chez la femme, Comtes Rendus, 294, 922
- Murphy, 1993, Possible use of glucocorticoid receptor antagonists in the treatment of major depression, J Psychiatr Neurosci, 18, 209
- Nobler, 1997, Quantifying the speed of symptomatic improvement with electroconvulsive therapy, Convuls Ther, 13, 208
- Rothschild, 1985, Delusional depression, McLean Hosp J, 10, 68
- Swartz, 1985, Electroconvulsive therapy-induced cortisol release, Convul Ther, 1, 15
Cited by
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Stress and the brain: from adaptation to disease
de Kloet, E. R., Joëls, M., & Holsboer, F. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1683 · Cited by 4,621
PRACTICE GUIDELINE FOR THE Treatment of Patients With Major Depressive Disorder
Gelenberg, A. J., Freeman, P. B., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H., & Rhoads, R. S. (2010) · Cited by 1,510
Discovering Endophenotypes for Major Depression
Hasler, G., Drevets, W. C., Manji, H. K., & Charney, D. S. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300506 · Cited by 1,123
Korte, S. M., Koolhaas, J. M., Wingfield, J. C., & McEwen, B. S. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2004.08.009 · Cited by 1,097
Metadata
- Authors
- Belanoff, J. K., Rothschild, A. J., Cassidy, F., DeBattista, C., Baulieu, E.-E., Schold, C., & Schatzberg, A. F.
- Affiliations
- Corcept Therapeutics (United States) (US)
- University of Massachusetts Chan Medical School (US)
- Duke University (US)
- Stanford University (US)
- Duke Clinical Research Institute (US)
- Venue
- Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2002-09
- Volume
- 52
- Issue
- 5
- Pages
- 386-392
- ISSN
- 0006-3223 (ISSN-L)
- OpenAlex
- W2005817345
- Cited by
- 320
- References
- 71
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 3 · 2022: 3 · 2021: 5 · 2020: 11 · 2019: 9 · 2018: 9 · 2017: 1 · 2016: 10 · 2015: 5 · 2014: 13 · 2013: 10 · 2012: 14
- FWCI
- 18.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Biological Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- The Journal of the American Medical Association (JAMA) Network (American Medical Association) (submittedVersion)
- Funders
- National Institute of Mental Health (T32-MH19983, R01MH050604, MH50604)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
- Keywords
- mifepristone, psychotic depression, glucocorticoid receptor antagonist, antidepressant efficacy, dose comparison, positive psychotic symptoms, Brief Psychiatric Rating Scale, Hamilton Depression Rating Scale
- MeSH terms
- Adult, Aged, Major Depressive Disorder, Dose-Response Relationship, Drug, Female, Hormone Antagonists, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Mifepristone, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An open label trial of C-1073 (mifepristone) for psychotic major depression*. https://app.cochat.ai/papers/10.1016/s0006-3223(02)01432-4
- The paper
- Belanoff, J. K., Rothschild, A. J., Cassidy, F., DeBattista, C., Baulieu, E.-E., Schold, C., & Schatzberg, A. F. (2002). An open label trial of C-1073 (mifepristone) for psychotic major depression*. Biological Psychiatry. https://doi.org/10.1016/s0006-3223(02)01432-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.